A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. - Wikidata - wikimedia - TriplyDB

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

http://www.wikidata.org/entity/Q34111959

about

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Emerging and Evolving Ovarian Cancer Animal Models Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.The disparate origins of ovarian cancers: pathogenesis and prevention strategies.Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Three-dimensional modeling of ovarian cancer.Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.The promise and challenge of ovarian cancer models.Mutant p53 expression in fallopian tube epithelium drives cell migration A transcriptomal analysis of bovine oviductal epithelial cells collected during the follicular phase versus the luteal phase of the estrous cycle.Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube.Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.Pathogenesis and heterogeneity of ovarian cancer.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.Genetically-defined ovarian cancer mouse models.Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling.CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.Tubal origin of ovarian cancer - the double-edged sword of haemoglobin.VSV based virotherapy in ovarian cancer: the past, the present and …future?Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium.Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer.Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.Ovarian Cancer Prevention in High-risk Women.PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state.Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.

P2860

Q26780387-B2CD1180-99CE-4411-8744-A2A485577442 Q26783909-744D90E0-F7E0-4DF3-8977-6F1108631B07 Q27009306-674988B1-553E-4230-B4A5-1025505449F7 Q27333756-A0FAAAFF-94E3-47C1-A068-5B1F80673925 Q30240709-CC2C50A0-0B06-4407-845D-32680685BE91 Q30250107-36F42335-65BA-484A-8961-66946A82DC50 Q30423597-B41DBB63-9186-48EA-8C88-A218C9BBE1AE Q35591610-B989337E-676B-43FA-9BB7-BEEDBBEC5EF4 Q35693892-807476B1-E286-4C11-8A82-897325A118C0 Q35771750-F3500830-4611-468E-9067-A442C04DF740 Q35855276-7B53BE3A-C34C-436E-9D64-636E35694BAE Q35913996-E8C98B84-C748-497D-A6F3-9FC8BEF9BD3B Q36021465-E98E2447-C1CD-428C-8C35-3AAB6849CEC3 Q36039749-468B2511-DD15-46CD-ADFB-63D9EEFCD966 Q36172482-8541A8A5-C63D-4003-AD84-EB8AF55C182D Q36354166-036925F1-8CC7-4416-9DF9-F062578895E6 Q36436803-EF07A7F1-04F6-4AF3-B1AA-C83F3167DBF9 Q36685324-1B2389A1-CABE-4E41-B8A6-77958E7F7A29 Q36750564-DA3D48CB-82ED-446B-9D81-BE80D9BA8B44 Q37018096-2819B539-7574-4397-8EE1-C60A37388463 Q37341866-1F19B6AD-D8B3-4E42-B125-7849CA3FD590 Q37376754-EEE59CFE-5C55-4976-A751-94C8DD40E8C0 Q37440072-4A6BA5B9-3EDC-4AE6-9DE0-BA1D57203E14 Q37546692-9B7E23E6-6E8E-465B-8B3E-4516C68818FB Q37620476-15ECB401-252D-4592-8DAE-0FCA9C704D07 Q38615167-2E0534E1-95C4-4923-9A9A-8357A7667391 Q38719860-9B53D2B0-CCCB-4866-A46B-82FD4001273A Q38751550-F5B05D81-650F-4EAA-AC87-29E1785F831C Q39068123-3A0C4BE2-C910-4828-B254-FC42DE5E172A Q41441101-5C734A22-8171-4E5D-89CB-BA2A79802421 Q42365263-100F0B94-91AE-4245-9F48-BEC7735679D0 Q42379619-43F5584B-A51B-409D-A5A7-BC99CAE31289 Q42654023-3918BB3F-70F7-4436-ACAF-B217CAA7B0A8 Q42671513-039D92DA-B461-471E-A3AB-B459558439C5 Q45068704-22F42502-2687-4044-866F-8AD4D12D6FEF Q47160060-E3380B7A-2E99-4EFF-93E9-5BA372920A50 Q47370837-D0A47F76-398C-4CEB-B926-3258500A0280 Q48028203-398830F9-203A-4BDD-9FDB-85CF027C95F1 Q48124146-FF366D1B-7C30-4EE0-8822-F88B6556AD29 Q48148897-8FF31786-2AC2-467E-82A6-F4224E0EF1D5

P2860

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

http://www.wikidata.org/entity/Q34111959

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A genetically engineered ovari ...... serous carcinoma development.

@ast

A genetically engineered ovari ...... serous carcinoma development.

@en

A genetically engineered ovari ...... serous carcinoma development.

@nl

type

label

A genetically engineered ovari ...... serous carcinoma development.

@ast

A genetically engineered ovari ...... serous carcinoma development.

@en

A genetically engineered ovari ...... serous carcinoma development.

@nl

prefLabel

A genetically engineered ovari ...... serous carcinoma development.

@ast

A genetically engineered ovari ...... serous carcinoma development.

@en

A genetically engineered ovari ...... serous carcinoma development.

@nl

P1433

Q34111959-8DE56094-F4D0-4259-ACCA-15BE8ED3CA8A

P1476

Q34111959-0C67CF93-E9FB-4C49-BF9C-BD4BAD224F3E

P2093

Q34111959-255B701B-C856-459D-A14B-939C870B36DD

Q34111959-27417B03-3199-4CA7-A38E-42518F46463A

Q34111959-2C031712-4A29-40D5-9471-0DB64CAE6352

Q34111959-68EF5AFF-1FF0-4EBC-BC25-25B7EE79C165

Q34111959-762F1D33-4087-44C7-99C9-A08AD672998A

Q34111959-7809C49E-A423-40E2-ADCB-0EFB2FBD8B4F

Q34111959-88B3D065-89BC-46B2-87F9-61BA5979F41A

Q34111959-CA16E7CC-99E5-4A4B-9B27-0A839243E886

Q34111959-D5453B34-5217-4D80-B108-DCE5B1A5EBDB

Q34111959-DB57EBDF-3D8C-4A25-8524-A28AF1E9916D

P2860

Q34111959-033DD5A9-9306-499B-B776-5324353B36F7

Q34111959-09FE13BD-582C-4BF2-8F37-86A638249966

Q34111959-16AFB682-1C1D-43FD-B622-394329A14059

Q34111959-1E930A54-B8E8-4B4E-BB80-9EAC82844DD3

Q34111959-2312197A-1FF8-42D9-B131-FF28C9D90098

Q34111959-2438872E-1BDE-45E6-A882-038186A073DA

Q34111959-2F238DA4-4C7B-452B-AB51-96CD22E2ACE2

Q34111959-3AF0F583-CCB4-498D-8C84-E87B69BEFCD8

Q34111959-4C942F6E-8667-4CE3-81CE-3E0D8A948379

Q34111959-5037D77D-2A89-4611-B815-08DCEADCAFCA

P304

Q34111959-E3F3E513-1380-418E-82F0-A84694FC6254

P31

Q34111959-60EF0C49-6767-4FDC-B24D-3BC133F38D41

P356

Q34111959-395C0640-3762-486F-8596-2595E3EF0B06

P433

Q34111959-B95956BF-43F1-4065-977F-269DEC9A648F

P478

Q34111959-4ED77044-4E9A-489D-A592-D90D22184028

P50

Q34111959-143A4CA1-0D31-42B6-A009-C5706085B3D5

Q34111959-F31C5EDE-FF09-4861-973E-D8CF3073F13D

P577

Q34111959-900745E3-ED7E-46CA-9B55-4061E913E702

P5875

Q34111959-0C156976-AE58-4DD0-AE6F-DEAA0EBD06C8

P698

Q34111959-4755DF17-6E86-44B3-BB5B-7567B9740F17

P921

Q34111959-4BF1185A-308A-443E-8EEB-A21D9781F40D

Q34111959-5188B394-61EE-4D5F-AE1D-160A4B50F9C3

P932

Q34111959-609150C1-61EC-40E3-BDCB-F93104AEB37D

P356

P1433

The Journal of Pathology

P1476

A genetically engineered ovari ...... e serous carcinoma development

@en

P2093

Blanca L Valle

http://www.w3.org/2001/XMLSchema#string

Cheryl A Sherman-Baust

http://www.w3.org/2001/XMLSchema#string

Elisabetta Kuhn

http://www.w3.org/2001/XMLSchema#string

Ichiro Miyoshi

http://www.w3.org/2001/XMLSchema#string

Ie-Ming Shih

http://www.w3.org/2001/XMLSchema#string

Kevin G Becker

http://www.w3.org/2001/XMLSchema#string

Patrice J Morin

http://www.w3.org/2001/XMLSchema#string

Robert J Kurman

http://www.w3.org/2001/XMLSchema#string

Tian-Li Wang

http://www.w3.org/2001/XMLSchema#string

Tomokazu Amano

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

A comprehensive analysis of PAX8 expression in human epithelial tumors

Technical aspects of immunohistochemistry

Analysis of microarray data using Z score transformation

Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

P304

228-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.4353

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

233

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260948271

http://www.w3.org/2001/XMLSchema#string

P698

24652535

http://www.w3.org/2001/XMLSchema#string

P921

P932

4149901

http://www.w3.org/2001/XMLSchema#string